Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 5Terminated 3Recruiting 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Multiple Myeloma 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Triple Negative Breast Neoplasms 1Recurrence 1Neoplasms, Plasma Cell 1Lymphoma, Mantle-Cell 1Immunoglobulin Light-chain Amyloidosis 1Amyloidosis 1

Interventions

venetoclax 2daratumumab 2Dexamethasone 2Bortezomib 2prednylidene 1pegaspargase 1nelarabine 1merphos 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1capivasertib 1calaspargase pegol 1auricularum 1Vincristine 1Thioguanine 1Spinal Puncture 1Specimen Handling 1Radiotherapy 1Radiation 1Prednisone 1Prednisolone 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Medrol Veriderm 1Magnetic Resonance Spectroscopy 1Hydrocortisone 1High-Energy Shock Waves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Bortezomib × Clear all
NCT07513129 2026-04-21

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
18 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡